Balaxi Pharmaceuticals Ltd. (BALAXI): Balaxi Pharmaceuticals Share Price Rises 9.97% Today

Balaxi Pharmaceuticals rose to Rs 25.04 today, up 9.97%. The company’s market capitalisation stands at Rs 123.33 crore.

Balaxi Pharmaceuticals Share Price rose to Rs 25.04 on 02 September 2026, up Rs 2.27 from the previous close of Rs 22.77. The gain works out to 9.97%. The stock opened at Rs 22.45, which was also the day low, and climbed to Rs 25.04, which was also the day high and the current price in the supplied snapshot. Turnover stood at Rs 0.19 crore.

This confirms a strong one-session move, but the supplied dataset does not identify a company-specific trigger. So the useful way to read today’s action is through price behaviour, valuation, profitability and how BALAXI sits against the wider Trading industry.

Balaxi Pharmaceuticals Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 25.04
Previous Close	Rs 22.77
Today's Move	Rs 2.27 (+9.97%)
Open	Rs 22.45
High	Rs 25.04
Low	Rs 22.45
Turnover	Rs 0.19 crore
Market Capitalisation	Rs 123.33 crore
Market Cap Category	Micro Cap

Balaxi Pharmaceuticals Ltd. (BALAXI) rose to Rs 25.04 from the previous close of Rs 22.77, a move of Rs 2.27 or 9.97%. The stock opened at Rs 22.45, reached a high of Rs 25.04, recorded a low of Rs 22.45.

Today’s move was straightforward: the stock opened at Rs 22.45, never went below that level, and rose to Rs 25.04. That means it moved Rs 2.59 above the open and Rs 2.27 above the previous close of Rs 22.77. Because the open matched the low and the current price matched the high, the snapshot shows sustained intraday strength rather than a volatile back-and-forth session.

At Rs 25.04, Balaxi Pharmaceuticals Share Price places the company at a market capitalisation of Rs 123.33 crore. In practical terms, that makes it a small market-cap name within a very broad industry set, which can naturally draw attention when daily percentage moves are sharp. The data supports that the stock was in focus because of the price rise itself; it does not support assigning a confirmed corporate catalyst.

Balaxi Pharmaceuticals Ltd. (BALAXI) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 123.33 crore
P/E Ratio	51.86x
P/B Ratio	0.5x
ROE	0.59%
ROCE	3.48%
EPS	Rs 0.44
Book Value Per Share	Rs 45.35
Dividend Yield	0%

Balaxi Pharmaceuticals Ltd. (BALAXI) fundamental metrics show P/E 51.86x, P/B 0.5x, ROE 0.59%, ROCE 3.48%. These figures provide context only and are not a buy or sell signal.

Balaxi Pharmaceuticals Ltd. has a market capitalisation of Rs 123.33 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 51.86x, P/B at 0.5x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 0.59% and ROCE of 3.48%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 0.44, book value per share of Rs 45.35, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 22.66x, median ROE of 4.26%, median ROCE of 6.23%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Trading
Industry	Trading
Benchmark Scope	same industry
Company P/E Ratio	51.86x
Benchmark Median P/E	22.66x
Benchmark Average P/E	107.57x
Benchmark P/E Range	0.12x to 7,961.77x
Company P/B Ratio	0.5x
Benchmark Median P/B	1.42x
Company ROE	0.59%
Benchmark Median ROE	4.26%
Company ROCE	3.48%
Benchmark Median ROCE	6.23%
Company Market Capitalisation	Rs 123.33 crore
Benchmark Median Market Cap	Rs 53.14 crore

Balaxi Pharmaceuticals Ltd. (BALAXI) is classified under sector: Trading and industry: Trading.

Balaxi Pharmaceuticals Ltd. (BALAXI) has a P/E ratio of 51.86x, which is above the benchmark median of 22.66x, a difference of +128.86%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Balaxi Pharmaceuticals Ltd. (BALAXI) has a ROE of 0.59%, which is below the benchmark median of 4.26%, a difference of -86.15%. Balaxi Pharmaceuticals Ltd. (BALAXI) has a ROCE of 3.48%, which is below the benchmark median of 6.23%, a difference of -44.14%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Adani Enterprises Ltd.	ADANIENT	3,95,422.37	52.06	4.11	15.07	13.3
Premier Energies Ltd.	PREMIERENE	46,303.05	27.64	9.68	42.6	33.72
Aegis Logistics Ltd.	AEGISLOG	44,419.05	34.24	6.49	20.71	19.76
ADITYA INFOTECH LIMITED	CPPLUS	42,223.79	92.33	21.86	25.68	29.48
Redington Ltd.	REDINGTON	28,003.16	16.05	2.57	13.6	18.96

Balaxi Pharmaceuticals Ltd. (BALAXI) has a P/E ratio of 51.86x compared with the displayed peer median of 34.24x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0.59% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 3.48% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Balaxi Pharmaceuticals Ltd. (BALAXI) has a market capitalisation of Rs 123.33 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching Balaxi Pharmaceuticals

• Price action: the stock rose Rs 2.27, or 9.97%, to Rs 25.04 from Rs 22.77.
• Intraday strength: open and low were Rs 22.45, while current price and high were Rs 25.04.
• Valuation contrast: P/E is 51.86 but P/B is 0.5.
• Profitability gap: ROE 0.59 and ROCE 3.48 are below industry medians of 4.26 and 6.23.
• Industry context: market cap of Rs 123.33 crore is above the industry median of Rs 53.14 crore.

About Balaxi Pharmaceuticals

Based on the supplied classification, Balaxi Pharmaceuticals Ltd. is mapped to the Trading sector and Trading industry. The dataset used for this article does not provide a fuller business description, segment mix or revenue breakdown. It does confirm that master data matched by finCode, with technical count 1 and fundamental count 8. Available fundamental fields are marketCapCr, pe, pb, roe, roce, eps, bookValue and dividendYield.

So, for this update, the most reliable interpretation comes from the numbers on price, valuation, profitability and peer comparison rather than from a fresh company narrative or a stated trigger.

Track Balaxi Pharmaceuticals Share Price on Univest

Use Balaxi Pharmaceuticals Ltd. (BALAXI) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

You can track Balaxi Pharmaceuticals Ltd. (BALAXI) live share-price page, the Univest top gainers screener and Univest market blogs for live price updates, market-cap changes, fundamentals and peer context. For readers following Balaxi Pharmaceuticals Share Price, that helps connect today’s 9.97% move with the company’s P/E, P/B, ROE, ROCE, EPS and book value data.

Frequently Asked Questions

Why is Balaxi Pharmaceuticals Share Price rising today?

Ans. Balaxi Pharmaceuticals Share Price rose 9.97% today to Rs 25.04 from Rs 22.77, a gain of Rs 2.27. The supplied data confirms the move but does not provide a verified company-specific catalyst.

What is the Balaxi Pharmaceuticals Share Price Today?

Ans. The supplied snapshot shows Balaxi Pharmaceuticals Share Price at Rs 25.04. The stock opened at Rs 22.45, traded between Rs 22.45 and Rs 25.04, and turnover was Rs 0.19 crore.

What is the market cap of Balaxi Pharmaceuticals?

Ans. Balaxi Pharmaceuticals has a market capitalisation of Rs 123.33 crore. That is above the same-industry median of Rs 53.14 crore but below the industry average of Rs 1615.14 crore. The company operates in the Trading sector.

How does BALAXI compare on valuation and profitability?

Ans. BALAXI has P/E 51.86, P/B 0.5, ROE 0.59 and ROCE 3.48. Its P/E is above the industry median of 22.66, its P/B is below the industry median of 1.42, and both profitability ratios are below the industry medians of 4.26.

Who are the key peers in this comparison?

Ans. The displayed peers are Adani Enterprises, Premier Energies, Aegis Logistics, ADITYA INFOTECH LIMITED and Redington. All five have larger market capitalisations than Balaxi Pharmaceuticals, and all five show higher ROE and ROCE in the supplied comparison.